Retrieved from Araj-Khodaei, M., Ayati, M
A., Stewart, M
The objective of this study was to determine the effects of a novel GHRH (GHRH 144 ) analog, tesamorelin, on endogenous GH pulsatility and insulin sensitivity in healthy men
Local reaction characteristics: Confined to the injection site and immediately surrounding area Symptoms include redness, swelling, itching, pain, and warmth at the injection site only No systemic symptoms (no fever, no hives elsewhere, no breathing difficulty) Resolves within 3 to 7 days Does not typically worsen after the first 24 to 48 hours Systemic allergic reaction characteristics: Symptoms extend beyond the injection site Hives, rash, or flushing on areas distant from the injection site Respiratory symptoms (coughing, wheezing, throat tightness) Cardiovascular symptoms (rapid pulse, low blood pressure, dizziness) Gastrointestinal symptoms (nausea, vomiting, cramping) beyond typical GI side effects Local reactions almost never require discontinuation of tirzepatide
High levels of vitamin E intake do not result in a noted toxicity
15 Tirzepatide (Mounjaro, Zepbound) is a related medication that mimics both GLP-1 and another gut hormone called GIP (glucose-dependent insulinotropic polypeptide), potentially leading to even greater weight loss effects for some individuals
